Mustang Bio Past Earnings Performance

Past criteria checks 0/6

Mustang Bio has been growing earnings at an average annual rate of 1.5%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 109.2% per year.

Key information

1.5%

Earnings growth rate

29.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate109.2%
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Mustang Bio: This Horse May Gallop Still

Sep 23

Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?

Aug 09
Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?

Mustang Bio: The Market Is Missing This Opportunity

May 03

Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?

Dec 29
Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?

Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies

Sep 14

Mustang Bio (MBIO) EHA Investor Presentations - Slideshow

Jun 18

Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers

Jun 11

Checking Back In On Mustang Bio

May 26

FDA accepts Mustang Bio's MB-106 application in cancer

May 10

Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation

Mar 22
Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation

What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?

Feb 23
What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?

Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price

Jan 28
Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price

Revenue & Expenses Breakdown

How Mustang Bio makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:MBIO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-23715
30 Jun 240-32724
31 Mar 240-40931
31 Dec 230-521041
30 Sep 230-631051
30 Jun 230-721157
31 Mar 230-741162
31 Dec 220-781264
30 Sep 220-781264
30 Jun 220-761164
31 Mar 220-711160
31 Dec 210-661156
30 Sep 210-671157
30 Jun 210-631150
31 Mar 210-631149
31 Dec 200-601047
30 Sep 200-56943
30 Jun 200-53943
31 Mar 200-49938
31 Dec 190-461036
30 Sep 190-421032
30 Jun 190-39930
31 Mar 190-34827
31 Dec 180-31724
30 Sep 180-34627
30 Jun 180-34923
31 Mar 180-34923
31 Dec 170-31920
30 Sep 170-24915
30 Jun 170-19613
31 Mar 170-1559
31 Dec 160-1339
30 Sep 160-623
30 Jun 160-513
31 Mar 160-413

Quality Earnings: MBIO is currently unprofitable.

Growing Profit Margin: MBIO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 1.5% per year.

Accelerating Growth: Unable to compare MBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: MBIO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies